Skip to main content

Table 3 Treatment related adverse events occurring in 10% or more patients

From: Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

TRAE 250 mg (n = 3) 300 mg (n = 25) 350 mg (n = 53) Total (n = 81)
G-Alla ≥ G3 G-All ≥ G3 G-All ≥ G3 G-All ≥ G3
Gastrointestinal disorders (n, %)         
Diarrhea 3 (100) 0 16 (64.0) 1 (4.0) 36 (67.9) 1 (1.9) 55 (67.9) 2 (2.5)
Oral ulcer 0 0 4 (16.0) 0 21 (39.6) 1 (1.9) 25 (30.9) 1 (1.2)
Vomiting 1 (33.3) 0 8 (32.0) 1 (4.0) 11 (20.8) 0 20 (24.7) 1 (1.2)
Nausea 1 (33.3) 0 8 (32.0) 1 (4.0) 7 (13.2) 1 (1.9) 16 (19.8) 2 (2.5)
Oral mucositis 0 0 3 (12.0) 0 7 (13.2) 0 10 (12.3) 0
Skin and subcutaneous tissue disorders (n, %)         
Rash 1 (33.3) 0 10 (40.0) 0 41 (77.4) 7 (13.2) 52 (64.2) 7 (8.6)
Palmar-plantar erythrodysesthesia syndrome 1 (33.3) 1 (33.3) 7 (28.0) 1 (4.0) 24 (45.3) 2 (3.8) 32 (39.5) 4 (4.9)
Investigations (n, %)         
Elevated AST 0 0 4 (16.0) 0 17 (32.1) 4 (7.5) 21 (25.9) 4 (4.9)
Elevated ALT 0 0 5 (20.0) 0 15 (28.3) 2 (3.8) 20 (24.7) 2 (2.5)
Leukopenia 0 0 3 (12.0) 0 6 (11.3) 0 9 (11.1) 0
Metabolism and nutrition disorders (n, %)         
Anorexia 0 0 2 (8.0) 0 10 (18.9) 1 (1.9) 12 (14.8) 1 (1.2)
Hypoalbuminemia 0 0 0 0 12 (22.6) 0 12 (14.8) 0
Infections and infestations (n, %)         
Paronychia 0 0 4 (16.0) 0 7 (13.2) 1 (1.9) 11 (13.6) 1 (1.2)
General disorders and administration site conditions (n, %)         
Fatigue 0 0 3 (12.0) 1 (4.0) 9 (17.0) 2 (3.8) 12 (14.8) 3 (3.7)
Blood and lymphatic system disorders (n, %)         
Anemia 1 (33.3) 1 (33.3) 4 (16.0) 1 (4.0) 20 (37.7) 3 (5.7) 25 (30.9) 5 (6.2)
Renal and urinary disorders (n, %)         
Proteinuria 0 0 3 (12.0) 0 13 (24.5) 0 16 (19.8) 0
  1. aG, grade